文献速递心脑血管急症

强化与标准降压治疗试验的最终报告

Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.
PubMed 文献 · N Engl J Med · 2021-01-01
一句话结论心血管高危患者强化降压至收缩压<120 mmHg较标准<140 mmHg降低主要心血管事件与全因死亡,但低血压、电解质异常、急性肾损伤/衰竭和晕厥等严重不良事件更多。

SPRINT试验将9361例心血管病风险增高但无糖尿病或既往卒中的患者随机分配至强化降压目标(收缩压<120 mmHg)或标准降压目标(收缩压<140 mmHg)。中位随访3.33年,强化组主要复合终点年发生率为1.77% vs 标准组2.40%(HR 0.73,95%CI 0.63-0.86),全因死亡年发生率为1.06% vs 1.41%(HR 0.75,95%CI 0.61-0.92)。强化组低血压、电解质异常、急性肾损伤或衰竭及晕厥等严重不良事件显著更频繁。试验期与试验后随访合计3.88年,治疗获益与不良事件模式相似,但心力衰竭发生率两组不再有差异。

要点

  • 心血管高危但无糖尿病或既往卒中患者,强化降压至收缩压<120 mmHg较<140 mmHg降低主要心血管复合终点(年发生率1.77% vs 2.40%;HR 0.73,95%CI 0.63-0.86)。
  • 强化降压组全因死亡年发生率为1.06% vs 标准组1.41%(HR 0.75,95%CI 0.61-0.92)。
  • 强化组低血压、电解质异常、急性肾损伤或衰竭及晕厥等严重不良事件显著更频繁。
  • 试验期与试验后随访合计3.88年,治疗获益与不良事件模式相似,但心力衰竭发生率两组不再有差异。

适用人群与场景

  • 心血管疾病风险增高但无糖尿病或既往卒中的患者,随机分配至强化或标准降压治疗目标。

诊断标准与关键阈值

  • 强化治疗目标:收缩压<120 mmHg;标准治疗目标:收缩压<140 mmHg。

处置流程与药物剂量

  • 强化治疗组以收缩压<120 mmHg为目标进行降压治疗。
  • 标准治疗组以收缩压<140 mmHg为目标进行降压治疗。

红旗征与不能漏的情况

  • 强化治疗组低血压、电解质异常、急性肾损伤或衰竭及晕厥等严重不良事件显著更频繁。

研究设计与关键结果

  • 随机对照试验,纳入9361例心血管风险增高但无糖尿病或既往卒中的患者,中位随访3.33年。
  • 强化组vs标准组主要复合终点年发生率1.77% vs 2.40%(HR 0.73,95%CI 0.63-0.86)。
  • 强化组vs标准组全因死亡年发生率1.06% vs 1.41%(HR 0.75,95%CI 0.61-0.92)。
  • 强化组低血压、电解质异常、急性肾损伤或衰竭及晕厥等严重不良事件显著更频繁。
  • 试验期与试验后随访合计3.88年,治疗获益与不良事件模式相似,但心力衰竭发生率两组不再有差异。

证据类型、等级与局限

  • 随机对照试验(SPRINT,NCT01206062),由美国国立卫生研究院资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于心血管风险增高但无糖尿病或既往卒中的患者,以收缩压<120 mmHg为目标的强化降压较<140 mmHg降低主要心血管事件和全因死亡,但需监测低血压、电解质异常、急性肾损伤或衰竭及晕厥。

指南或共识出处

  • SPRINT试验最终报告,N Engl J Med,NCT01206062。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In a previously reported randomized trial of standard and intensive systolic blood-pressure control, data on some outcome events had yet to be adjudicated and post-trial follow-up data had not yet been collected.

METHODS: We randomly assigned 9361 participants who were at increased risk for cardiovascular disease but did not have diabetes or previous stroke to adhere to an intensive treatment target (systolic blood pressure, <120 mm Hg) or a standard treatment target (systolic blood pressure, <140 mm Hg). The primary outcome was a composite of myocardial infarction, other acute coronary syndromes, stroke, acute decompensated heart failure, or death from cardiovascular causes. Additional primary outcome events occurring through the end of the intervention period (August 20, 2015) were adjudicated after data lock for the primary analysis. We also analyzed post-trial observational follow-up data through July 29, 2016.

RESULTS: At a median of 3.33 years of follow-up, the rate of the primary outcome and all-cause mortality during the trial were significantly lower in the intensive-treatment group than in the standard-treatment group (rate of the primary outcome, 1.77% per year vs. 2.40% per year; hazard ratio, 0.73; 95% confidence interval [CI], 0.63 to 0.86; all-cause mortality, 1.06% per year vs. 1.41% per year; hazard ratio, 0.75; 95% CI, 0.61 to 0.92). Serious adverse events of hypotension, electrolyte abnormalities, acute kidney injury or failure, and syncope were significantly more frequent in the intensive-treatment group. When trial and post-trial follow-up data were combined (3.88 years in total), similar patterns were found for treatment benefit and adverse events; however, rates of heart failure no longer differed between the groups.

CONCLUSIONS: Among patients who were at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic blood pressure of less than 140 mm Hg, both during receipt of the randomly assigned therapy and after the trial. Rates of some adverse events were higher in the intensive-treatment group. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Lewis CE, Fine LJ, Beddhu S, et al. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2021. PMID: 34010531. doi:10.1056/NEJMoa1901281

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。